Shah Avanthi,  Alizadeh Ash,  Sweet-cordero Alejandro,  Wittber Frederick,  Azad Tej,  Chabon Jake,  Leung Stan,  Spillinger Aviv,  Liu Heng-yi,  Breese Marcus,  Diehn Maxamilian

Final Pr. ID: Poster #: SCI-061

Currently, biopsy serves as the gold standard to accurately diagnose disease in pediatric sarcoma patients, but the risks of anesthesia and surgery, along with a failure to characterize the true heterogeneity of disease make this method less than ideal. Progression and response to therapy are monitored by radiologic exams which lack the sensitivity to detect early relapse. Cell free DNA (cfDNA) is released into the plasma as they undergo apoptosis and necrosis. ctDNA represents a small fraction of cfDNA in cancer patients and contains tumor specific alterations. It holds promise as a highly sensitive and specific biomarker. A limitation in applying liquid biopsy in clinical practice is the need to develop PCR or other DNA analysis methods to detect alterations specific to a single patient. We have developed a more widely applicable off the shelf test that does not involve a patient specific design. Read More

Authors:  Shah Avanthi , Alizadeh Ash , Sweet-cordero Alejandro , Wittber Frederick , Azad Tej , Chabon Jake , Leung Stan , Spillinger Aviv , Liu Heng-yi , Breese Marcus , Diehn Maxamilian

Keywords:  sarcoma, ctdna, cappseq